Pharmaceuticals
LycovaryTM Daily provides anti-ageing oxygenation of the ovaries to help women with PMS, painful periods and comfortable menopause transition
CAMBRIDGE, England, Dec. 24, 2020 /PRNewswire/ -- Cambridge Diagnostic Imaging,
CaDi, (cadifamily.com
2020-12-24 08:00
5236
Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis
SAN FRANCISCO and SUZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2020-12-23 12:30
9593
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line d...
2020-12-22 20:38
5047
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
SHANGHAI, Dec. 22, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announces today dosing of overweight and obese subjects in a Phase Ib trial of ASC41, an oral tablet,...
2020-12-22 19:18
3654
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004
SEATTLE, Dec. 21, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and...
2020-12-21 23:00
3277
LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA
TAIPEI, Dec. 21, 2020 /PRNewswire/ -- Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, fromSingapore's Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approv...
2020-12-21 22:08
2489
BioVaxys Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens
VANCOUVER, British Columbia, Dec. 21, 2020 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) ("BioVaxys") announced today that further analysis of the data from a preclinical animal study (also known as the "murine model study") of its haptenized viral protein vaccine tech...
2020-12-21 21:00
3756
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. (Nasdaq...
2020-12-21 08:00
4207
Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM
SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2020-12-18 15:34
5856
Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals
* Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal * Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in the n...
2020-12-18 06:52
2169
dMed Completed a US$100 Million Series C Financing
SHANGHAI, Dec. 17, 2020 /PRNewswire/ -- dMed, the clinical CRO with strong presence inChina and the US, the world's two largest pharmaceutical markets and drug development sites, announced today its successful completion of aUS$100 million Series C financing. Led by Fidelity Management & Research...
2020-12-17 13:00
3347
Global UV Cured Resins Market will grow to US$ 7892.70 Mn by 2028 at 8.9% CAGR - says Absolute Markets Insights
PUNE, India, Dec. 17, 2020 /PRNewswire/ --
2020-12-17 11:00
3658
Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange
CAMBRIDGE, Mass. and SUZHOU, China, Dec. 17, 2020 /PRNewswire/ -- HBM Holdings Limited ("Harbour BioMed", "HBM" or the "Company"; Stock Code: 02142.HK), a global clinical-stage biopharmaceutical company, completed its global offering (the "Global Offering") and its listing on the Main Board of ...
2020-12-17 08:19
10973
Covance, LabCorp's Drug Development Business, Acclaimed by Frost & Sullivan for Its Unmatched Breadth of Services to Support Clinical Trials
LONDON, Dec. 16, 2020 /PRNewswire/ -- Based on its recent analysis of the global contract research organization (CRO) market, Frost & Sullivan recognizes LabCorp's drug development business, Covance, with the 2020 Global CRO Company of the Year Award. The company has built technology-enabled solu...
2020-12-17 00:29
2431
EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)
PROVIDENCE, R.I., Dec. 16, 2020 /PRNewswire/ -- EpiVax, Inc. reports a record-breaking year for the "ISPRI" immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020 than ever before in the company's twen...
2020-12-16 02:15
2436
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
Acute respiratory distress syndrome (ARDS)-induced thrombosis (blood clotting) may occur in up to one-third of COVID-19 patients requiring ICU admission and is a contributing cause of mortality Opaganib demonstrated reduced thrombosis in a preclinical model of ARDS Opaganib has also been shown t...
2020-12-16 00:42
5124
ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures
NEW YORK, Dec. 15, 2020 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client, ADC Therapeutics SA (NYSE: ADCT), has successfully entered into an agreement to jointly form a new company, Overland ADCT BioPharma (CY) Limited with Overland Pharmaceuticals, a fully integrate...
2020-12-15 22:00
4637
PCCS Group Has Reached a Strategic Cooperation With Shenqi Medical to Seek a Grand Blueprint of Medical Health in the Asia-pacific Region
SHANGHAI, Dec. 15, 2020 /PRNewswire/ -- Malaysia's PCCS Group Berhad (hereinafter referred to as "PCCS") andChina's Shanghai Shenqi Medical Co., Ltd. (hereinafter referred to as "Shenqi Medical") today announced the signing of a memorandum of understanding (MOU) to cooperatively pursue the potent...
2020-12-15 18:30
3854
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials
CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, Netherlands, Dec. 15, 2020 /PRNewswire/ -- Harbour BioMed (HBM)(HKEX:02142), andUtrecht University (UU) today announced that they licensed to AbbVie their fully human, SARS-CoV-2 neutralizing antibody, 47D11 and program, for the prevention and treatment o...
2020-12-15 08:00
9260
Regent Pacific's Commercial Strategic Partner Receives Approval from Taiwan Food and Drug Administration
HONG KONG, Dec. 14, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Orient EuroPharma Co., L...
2020-12-14 20:20
4316
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 286 media titles]
2025-12-10 16:00
